GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cassava Sciences Inc (NAS:SAVA) » Definitions » Intrinsic Value: Projected FCF
中文

Cassava Sciences (Cassava Sciences) Intrinsic Value: Projected FCF

: $-4.87 (As of Today)
View and export this data going back to 2000. Start your Free Trial

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-24), Cassava Sciences's Intrinsic Value: Projected FCF is $-4.87. The stock price of Cassava Sciences is $20.525. Therefore, Cassava Sciences's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Cassava Sciences's Intrinsic Value: Projected FCF or its related term are showing as below:

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Cassava Sciences was 29.73. The lowest was 29.73. And the median was 29.73.

SAVA's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.34
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Cassava Sciences Intrinsic Value: Projected FCF Historical Data

The historical data trend for Cassava Sciences's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cassava Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.06 -1.10 1.47 -0.56 -4.87

Cassava Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.56 -1.38 -2.52 -3.82 -4.87

Competitive Comparison

For the Biotechnology subindustry, Cassava Sciences's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cassava Sciences Price-to-Projected-FCF Distribution

For the Biotechnology industry and Healthcare sector, Cassava Sciences's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Cassava Sciences's Price-to-Projected-FCF falls into.



Cassava Sciences Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Cassava Sciences's Free Cash Flow(6 year avg) = $-33.12.

Cassava Sciences's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec23)*0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-33.11712+137.468*0.8)/42.193
=-4.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cassava Sciences  (NAS:SAVA) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Cassava Sciences's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=20.525/-4.8660257920925
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cassava Sciences Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Cassava Sciences's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cassava Sciences (Cassava Sciences) Business Description

Traded in Other Exchanges
Address
6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.
Executives
Sanford Robertson director ONE LETTERMAN DRIVE, BUILDING C SUITE 410, SAN FRANCISCO CA 94129
Richard Barry director 285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Robert Christopher Cook officer: SVP & General Counsel 6801 N. CAPITAL OF TEXAS HWY, BUILDING 1, SUITE 300, AUSTIN TX 78731
James William Kupiec officer: Chief Clinical Dev. Officer 7801 N CAPITAL OF TEXAS HIGHWAY, SUITE 260, AUSTIN TX 78731
Eric Schoen officer: Chief Financial Officer 7801 N. CAPITAL OF TX HWY, SUITE 260, AUSTIN TX 78731
Remi Barbier director, 10 percent owner, officer: CEO, Chairman of the Board
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
O Donnell Michael J director
Robert Z Gussin director
Scannon Patrick J Md Phd director C/O XOMA, LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Nadav Friedmann director, officer: Chief Scientific Officer
Sabretooth Master Fund, L.p. 10 percent owner 405 LEXINGTON AVENUE, 50TH FLOOR, NEW YORK NY 10174